CSL's (ASX:CSL) Switzerland-based pharmaceutical unit, CSL Vifor, and US biopharmaceutical firm Travere Therapeutics said the European Commission has granted standard marketing authorization for Filspari, a treatment for primary IgA nephropathy (IgAN), a rare and progressive kidney disease, according to a Tuesday statement by the company.
The decision converts a previous conditional marketing authorization and extends to all European Union member states, as well as Iceland, Liechtenstein, and Norway, the company said.
Filspari was developed by Travere Therapeutics and exclusively licensed to CSL Vifor for commercialization in Europe, Australia, and New Zealand.
CSL's shares rose 1% in recent Wednesday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.